Trade Summary

4 days ago, Herrmann Ken, serving as Dir at Aktis Oncology, Inc. (AKTS), sold 3,065 shares at $25.21 per share, for a total transaction value of $77,258.54.

This sale represents a 100.00% decrease in Herrmann Ken's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, July 17, 2026 and publicly disclosed via SEC Form 4 filing on Monday, July 20, 2026 at 5:34 PM ET, 3 days after the trade was made.

Aktis Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.